Mild cognitive impairment, often called MCI, is a condition that sits between normal aging and dementia. Many people with MCI experience memory problems and cognitive decline, and some eventually develop Alzheimer disease. Because of this risk, scientists are constantly searching for treatments that might slow cognitive decline before dementia begins.
A newly published clinical study in JAMA Neurology explored whether low dose lithium could help delay cognitive decline in older adults with MCI. Lithium has long been used to treat mood disorders, but researchers believe it may also have neuroprotective properties that could benefit the brain.
This article explains the key findings of the trial, how lithium may affect brain health, and what the results mean for future research into preventing Alzheimer related cognitive decline.
Mild cognitive impairment is a condition where individuals experience noticeable changes in memory, thinking, or reasoning. These changes are greater than typical age related decline but not severe enough to interfere significantly with daily life.
Common symptoms of MCI include:
Not everyone with MCI develops dementia. However, research shows that people with MCI have a higher risk of progressing to Alzheimer disease compared with cognitively healthy adults.
Because the early stages of cognitive decline may present a window for intervention, researchers are investigating treatments that might protect brain function during this period.
Lithium is best known as a treatment for bipolar disorder. However, scientists have discovered that it may influence several biological processes related to brain health.
Researchers believe lithium might protect the brain through several mechanisms:
Lithium can inhibit enzymes called GSK-3 alpha and beta. These enzymes are associated with processes that contribute to neurodegeneration and Alzheimer pathology.
Lithium may increase levels of brain derived neurotrophic factor, often abbreviated as BDNF. This protein supports neuron survival, growth, and connectivity.
Some evidence suggests lithium could help stabilize neurons and protect brain cells from damage.
Previous observational studies and smaller clinical trials have hinted that lithium might reduce the risk of dementia or slow cognitive decline. However, robust randomized clinical trials examining cognitive outcomes, brain imaging, and biological markers have been limited.
The recent study investigated whether low dose lithium carbonate could slow cognitive decline in older adults with mild cognitive impairment.
Researchers conducted a randomized, double blind, placebo controlled pilot clinical trial at the University of Pittsburgh School of Medicine.
Key characteristics of the study included:
Participants were randomly assigned to one of two groups:
Both groups received identical capsules to ensure the trial remained blinded.
Among those who started treatment:
Participants were monitored regularly for safety, cognitive performance, and biological changes.
The study examined several indicators of brain function and health.
Three major cognitive measures were used:
These tests evaluate memory, learning ability, and general cognitive performance.
Researchers also measured structural brain changes using MRI scans. Two important measurements included:
The hippocampus plays a central role in memory formation and is one of the first brain regions affected in Alzheimer disease.
Blood samples were analyzed for brain derived neurotrophic factor levels. This biomarker may indicate brain health and neuronal resilience.
The study followed participants for two years and analyzed changes in cognition, brain structure, and biological markers.
The researchers examined six main outcomes. None met the strict statistical significance threshold defined before the trial began.
This means the results did not conclusively prove that lithium slowed cognitive decline.
However, some findings suggested potential trends that may be important for future research.
One of the most interesting observations involved verbal memory.
Using the California Verbal Learning Test, researchers found:
This difference suggested a slower decline in verbal memory among those taking lithium.
However, the result did not meet the study's stricter statistical threshold for confirming effectiveness.
MRI scans showed that both groups experienced decreases in hippocampal and cortical brain volume over time.
These declines are expected in people with mild cognitive impairment.
The differences between the lithium and placebo groups were not statistically significant.
Still, exploratory analyses suggested possible benefits among certain participants, particularly those with evidence of amyloid pathology.
Researchers conducted exploratory analyses on a subgroup of participants who showed amyloid plaques in the brain. Amyloid accumulation is a hallmark feature of Alzheimer disease.
In this subgroup, lithium appeared to show larger effect sizes for several outcomes, including:
Because the subgroup was small, these results cannot be considered definitive. However, they suggest that future trials focusing on individuals with Alzheimer related pathology might reveal stronger effects.
Safety was an important focus of the study because lithium can cause side effects at higher doses.
The results showed that low dose lithium was generally well tolerated.
Serious adverse events occurred in both groups:
None were definitively linked to lithium treatment.
Some participants experienced:
One participant in the placebo group died during the study, but the death was unrelated to the trial.
Overall, researchers concluded that low dose lithium was safe and feasible for older adults with MCI under medical supervision.
Like many clinical studies conducted during the past decade, this trial encountered obstacles.
The pandemic affected recruitment and testing procedures. Researchers had to transition from in person screenings to telephone assessments.
When the study was designed several years ago, blood tests for Alzheimer biomarkers were not widely available. As a result, many participants did not have confirmed Alzheimer pathology.
This may have diluted the treatment effect because some individuals likely had cognitive impairment from causes unrelated to Alzheimer disease.
One important takeaway from this research is that cognitive decline in mild cognitive impairment can occur slowly.
Short clinical trials lasting only a few months may not be long enough to detect meaningful changes.
Previous studies lasting 15 to 24 months have shown more promising results compared with shorter trials.
The two year duration of this study provided valuable data on how cognitive performance changes over time in MCI populations.
Although the trial did not prove that lithium slows cognitive decline, it offers several important insights for future studies.
The pilot study included only 80 participants. Larger trials with hundreds of participants could better detect meaningful effects.
Future research may focus specifically on people with biological evidence of Alzheimer disease.
Modern blood tests for biomarkers such as phosphorylated tau may make it easier to identify these individuals.
The study found that many older adults struggled to tolerate doses higher than 300 milligrams per day.
Future trials will likely explore low dose regimens between 150 and 300 milligrams daily.
Lithium remains an intriguing candidate for preventing or slowing neurodegenerative disease.
Several characteristics make it attractive:
However, much more evidence is required before lithium can be recommended for preventing cognitive decline.
Clinical experts emphasize that individuals should never self medicate with lithium without medical supervision.
For people diagnosed with mild cognitive impairment, the results highlight both progress and uncertainty.
While the study did not confirm lithium as a treatment, it provided valuable data that will guide larger trials.
Early intervention remains a promising strategy in the fight against Alzheimer disease. As scientific tools improve, researchers are becoming better at identifying which treatments might protect the brain before irreversible damage occurs.
The recent pilot trial investigating low dose lithium for mild cognitive impairment adds an important piece to the puzzle of dementia prevention.
Although the study did not demonstrate statistically significant benefits across its main outcomes, it showed that low dose lithium is feasible and generally safe for older adults in a controlled research setting.
Perhaps most importantly, the research identified potential signals suggesting lithium might slow verbal memory decline and may work better in individuals with amyloid related pathology.
Future larger trials will determine whether lithium could play a meaningful role in protecting cognitive function and delaying the onset of dementia.
As the global population ages and Alzheimer disease rates rise, research like this represents an essential step toward discovering effective strategies to preserve brain health.
Gildengers AG, Ibrahim TS, Anderson SJ, et al. Low Dose Lithium for Mild Cognitive Impairment: A Pilot Randomized Clinical Trial. Published online March 2, 2026 in JAMA Neurology. DOI: 10.1001/jamaneurol.2026.0072.
This article is for informational and educational purposes only and does not constitute medical advice. The findings discussed are based on a single pilot clinical trial and should not be interpreted as proof that lithium prevents or treats mild cognitive impairment or Alzheimer disease. Individuals should consult qualified healthcare professionals before making decisions related to medications, supplements, or medical treatments.
Most Accurate Healthcare AI designed for everything from admin workflows to clinical decision support.